TDOC Share Price | Teladoc Health, Inc. Stock Analysis & Recommendation

Q: How big is Teladoc Health, Inc.?

Market Cap: As of Jun 18, Teladoc Health, Inc. has a market capitalization of 1,242.08 million, categorizing it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Teladoc Health, Inc. reported net sales of 2,552.81 million and a net profit of -1,012.37 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 1,491.08 million and total assets of 3,763.36 million.

Q: What does Teladoc Health, Inc. do?

Overview: Teladoc Health, Inc. provides virtual healthcare services and operates within the Pharmaceuticals & Biotechnology industry, classified as a small-cap company.Financial Snapshot: Most recent Net Sales: 629 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -93 Million (Quarterly Results - Mar 2025) Market-cap: USD 1,242.08 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.25 Return on Equity: -10.14% Price to Book: 0.87Contact Details: Address: 2 Manhattanville Rd Ste 203, PURCHASE NY: 10577-2118 Tel: 1 203 6352002 Website: https://teladochealth.com/

Q: Is Teladoc Health, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Teladoc Health, Inc. has changed from sideways to mildly bullish. The weekly and monthly MACD indicators are both mildly bullish, supporting this stance. The KST, Dow Theory, and OBV also indicate a mildly bullish outlook on a weekly and monthly basis. However, the daily moving averages are mildly bearish, which presents some caution. The Bollinger Bands show a bullish signal on the weekly but a mildly bearish signal on the monthly.In terms of performance, Teladoc has outperformed the S&P 500 over the past week and month, with returns of 4.51% and 9.59% compared to the S&P's 1.09% and 4.15%, respectively. However, the longer-term returns are significantly negative, with a year-to-date return of -5.72% versus the S&P's 14.18%, and a three-year return of -68.03% compared to the S&P's 82.57%. Overall, the current technical stance is mildly bullish, but caution is warranted due to mixed signals from different indicators and poor long-term performance.

Results Declared: Teladoc Health, Inc. has declared results on 29 Apr 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.39 M

Shareholding (Mar 2026)

FII

16.89%

Held by 201 FIIs

DII

44.99%

Held by 55 DIIs

Promoter

1.10%

How big is Teladoc Health, Inc.?

22-Jun-2025

As of Jun 18, Teladoc Health, Inc. has a market capitalization of 1,242.08 million, with net sales of 2,552.81 million and a net profit of -1,012.37 million over the latest four quarters. The company reported shareholder's funds of 1,491.08 million and total assets of 3,763.36 million as of Dec 24.

View full answer

What does Teladoc Health, Inc. do?

22-Jun-2025

Teladoc Health, Inc. offers virtual healthcare services and is classified as a small-cap company with a market cap of approximately $1.24 billion. As of March 2025, it reported net sales of $629 million and a net loss of $93 million.

View full answer

Who are in the management team of Teladoc Health, Inc.?

22-Jun-2025

As of March 2022, the management team of Teladoc Health, Inc. includes David Snow (Independent Chairman), Jason Gorevic (CEO), and directors Christopher Bischoff, Karen Daniel, Sandra Fenwick, Hemant Taneja, and Glen Tullman, who oversee the company's strategic direction and operations.

View full answer

Is Teladoc Health, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Teladoc Health, Inc. shows a mildly bullish technical trend supported by weekly and monthly indicators, but caution is advised due to mixed signals and poor long-term performance.

View full answer

Compare Teladoc Health, Inc. with Similar Stocks

Amedisys, Inc.Guardant Health, Inc.The Ensign Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Flat results in Jun 25

DEBTORS TURNOVER RATIO(HY) Lowest at 10.96 times

Risky - Negative Operating Profits

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 962 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.20

Return on Equity

-9.12%

Price to Book

0.69

Revenue and Profits:

Net Sales:

614 Million

(Quarterly Results - Mar 2026)

Net Profit:

-64 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

44.71%

6 Months

-3.72%

1 Year

2.4%

2 Years

-40.57%

3 Years

-72.21%

4 Years

-78.33%

5 Years

-95.2%

Teladoc Health, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

23.86%

EBIT Growth (5y)

-256.85%

EBIT to Interest (avg)

-13.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.25

Sales to Capital Employed (avg)

0.82

Tax Ratio

1.30%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

98.19%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.69

EV to EBIT

-6.94

EV to EBITDA

6.51

EV to Capital Employed

0.74

EV to Sales

0.49

PEG Ratio

Dividend Yield

ROCE (Latest)

-10.69%

ROE (Latest)

-9.12%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 66 Schemes (37.02%)

Foreign Institutions

Held by 201 Foreign Institutions (16.89%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -2.48% vs -2.58% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 31.40% vs -13.55% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "613.80",
          "val2": "629.40",
          "chgp": "-2.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "45.50",
          "val2": "35.20",
          "chgp": "29.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "5.80",
          "chgp": "-6.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-13.00",
          "val2": "-65.70",
          "chgp": "80.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-63.80",
          "val2": "-93.00",
          "chgp": "31.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-79.40%",
          "val2": "-87.30%",
          "chgp": "0.79%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -1.54% vs -1.26% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 79.99% vs -354.26% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,530.00",
          "val2": "2,569.60",
          "chgp": "-1.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "213.00",
          "val2": "174.10",
          "chgp": "22.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "19.70",
          "val2": "23.80",
          "chgp": "-17.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-99.60",
          "val2": "-812.10",
          "chgp": "87.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-200.30",
          "val2": "-1,001.20",
          "chgp": "79.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-64.60%",
          "val2": "-81.30%",
          "chgp": "1.67%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

613.80

629.40

-2.48%

Operating Profit (PBDIT) excl Other Income

45.50

35.20

29.26%

Interest

5.40

5.80

-6.90%

Exceptional Items

-13.00

-65.70

80.21%

Consolidate Net Profit

-63.80

-93.00

31.40%

Operating Profit Margin (Excl OI)

-79.40%

-87.30%

0.79%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is -2.48% vs -2.58% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is 31.40% vs -13.55% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

2,530.00

2,569.60

-1.54%

Operating Profit (PBDIT) excl Other Income

213.00

174.10

22.34%

Interest

19.70

23.80

-17.23%

Exceptional Items

-99.60

-812.10

87.74%

Consolidate Net Profit

-200.30

-1,001.20

79.99%

Operating Profit Margin (Excl OI)

-64.60%

-81.30%

1.67%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is -1.54% vs -1.26% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 79.99% vs -354.26% in Dec 2024

All Annual Results

Company CV

About Teladoc Health, Inc.

Teladoc Health, Inc.

Pharmaceuticals & Biotechnology

Teladoc Health, Inc. provides virtual healthcare services. The Company provides virtual access to care with a portfolio of services and solutions, which includes various medical subspecialties from non-urgent, episodic needs, such as flu and upper respiratory infections, to chronic, complicated medical conditions, such as cancer and congestive heart failure. It provides virtual healthcare services on a business-to-business (B2B) basis to its clients and provides services to consumers directly and through channel partners. The Company’s consumer brands, including Teladoc, Advance Medical, Best Doctors, BetterHelp and HealthiestYou, provides access to advice and resolution to a range of healthcare needs. Its technology enables consumers to manage their own electronic medical records. It also provides access to a message center, provider finder, image upload capability and enable real-time sharing capabilities with providers that includes visit scheduling.

Company Coordinates

Company Details

2 Manhattanville Rd Ste 203 , PURCHASE NY : 10577-2118

Tel: 1 203 6352002

https://teladochealth.com/

Registrar Details